Jacqueline Mercier

Jacqueline Mercier is a partner in the firm’s Business Law department and a member of Goodwin’s Technology and Life Sciences groups and a member of the Goodwin Life Sciences and Public Company Advisory practices, where she is co-chair of the Structured Financing and Royalty Monetization practice. Jacqueline focuses her practice on late-stage and publicly traded company representation, including in matters related to corporate governance, mergers and acquisitions, royalty-based financings and other complex transactions, securities offerings, securities law compliance, proxy contests, and general corporate matters. Jacqueline originally joined Goodwin in 2007.

Recent representative transactional matters include:

• Royalty Pharma in its synthetic royalty financing of up to $300 million to Zenas BioPharma, Inc. to support Zenas BioPharma, Inc.’s obexelimab development program for IgG4-RD and other autoimmune diseases
• Royalty Pharma on a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and up to $750 million in senior secured debt, all to support Revolution Medicines’ plans for global development and commercialization of daraxonrasib and its pipeline programs for patients with RAS-addicted cancers
• Vigil Neurosciences in its acquisition by Sanofi for $470 million upfront and up to $600 million in potential milestone payments
• Royalty Pharma in its $905 million acquisition of an interest in Agios Pharmaceuticals’ royalty on VORANIGO (vorasidenib)
• GENFIT in its royalty financing agreement with HealthCare Royalty (HCRx) for up to €185 million in exchange for a portion of the royalties on sales of Iqirvo® (elafibranor)
• Royalty Pharma in its up to $1 billion strategic funding collaborations with Cytokinetics to support the commercialization of aficamten, the commercial launch of omecamtiv mecarbil and the further development of aficamten 
• AnaptysBio in its $50 million sale to Sagard Healthcare of royalties on Jemperli (dostarlimab)
• Moderna’s collaboration with Blackstone Life Sciences to fund Moderna’s influenza program for up to $750 million
• Repligen in its acquisitions of FlexBiosys and Metenova
• Royalty Pharma’s acquisition of a synthetic royalty on net sales of Emalex Biosciences’ ecopipam for $50 million plus up to $44 million in milestones
• Royalty Pharma’s acquisition of additional royalties on Roche’s Evrysdi for $1.0 billion upfront, with options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date
• Q32 Bio Inc.’s merger with Homology Medicines, Inc.
• Royalty Pharma’s acquisition of a synthetic royalty from Ascendis Pharma on net sales of Skytrofa® for $150 million
• Royalty Pharma in its acquisition of a synthetic royalty on US net sales of Ferring’s Adstiladrin® (nadofaragene firadenovec-vncg) for up to $500 million comprised of an upfront payment of $300 million and a $200 million milestone payment
• Avadel Pharmaceuticals in its $75 million revenue interest financing with RTW Investments to support the commercial launch of Lumryz
• FibroGen in its $50 million royalty monetization financing with NovaQuest Capital Management, backed by royalties on sales of Evrenzo
• Royalty Pharma’s acquisition of an interest in Ionis Pharmaceuticals’ royalty in Biogen’s SPINRAZA® (nusinersen) and Novartis’ pelacarsen for up to $1.12 billion, including an upfront payment of $500 million and up to $625 million in additional pelacarsen milestone payments
• Royalty Pharma’s acquisition of a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (NASDAQ: ARWR) for $250 million cash upfront and up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones
• Represented Citrix Systems, Inc., in its $16.5 billion sale to Vista Equity Partners and Evergreen Coast Capital
• Royalty Pharma’s acquisition of a royalty interest in TRELEGY ELLIPTA (Trelegy) from Theravance Biopharma, Inc. (Nasdaq: TBPH) and Innoviva, Inc. (Nasdaq: INVA) for $1.31 billion in cash up front and up to $300 million in additional payments contingent on the achievement of certain sales milestones
• Frazier Life Sciences in its deSPAC transaction with NewAmsterdam Pharma
• Royalty Pharma’s purchase of certain revenue streams from Biocryst Pharmaceuticals
• Vigil Neuroscience in its $90 million Series B financing, $90 million IPO, and $75 million PIPE 
• Royalty Pharma’s purchase of MorphoSys’ rights to receive future royalties on Janssen’s Tremfya in connection with a $2 billion strategic funding partnership as part of MorphoSys’ acquisition of Constellation Pharmaceuticals
• Royalty Pharma’s purchase of certain royalty interests from GlaxoSmithKline
• Sale of Cadent Therapeutics to Novartis
• Royalty Pharma’s purchase of certain royalty streams from BioHaven Pharmaceuticals
• Sale of AMAG Pharmaceuticals to Covis Pharma, an Apollo Global Management company
• Royalty Pharma’s purchase of certain royalty rights from PTC Therapeutics
• Royalty Pharma’s purchase of certain royalty rights from Ultragenyx Pharmaceutical
• AMAG Pharmaceuticals in the divestiture of its Intrarosa business line
• Wayfair in its $535 million private placement of convertible senior notes
• Novelion Therapeutics in its business combination with Amryt Pharma plc
• Centerbridge Partners in its acquisition of Civitas Solutions
• Keryx Biopharmaceuticals in its merger with Akebia Therapeutics
• GLPI in its purchase of Tropicana Entertainment casinos
• Cascadian Therapeutics in its sale to Seattle Genetics
• Citrix in its $2.6 billion Reverse Morris Trust merger with LogMeIn 
• First Eagle in its purchase of Newstar Financial
• Cornerstone OnDemand in its $300 million strategic investment led by Silver Lake 
• Lionbridge in its sale to HIG 
• Teva in its acquisition of Auspex Pharmaceuticals
• Centerview Partners in connection with the sale of Pharmacyclics to AbbVie
• Trulia in its sale to Zillow
• Courier Corporation in its sale to R.R. Donnelley
• Citrix’s $1.4 billion convertible notes offering
• Mac-Gray Corporation in its sale to CSC ServiceWorks, Inc.
• athenahealth in its acquisition of Epocrates, Inc.
• Avila Therapeutics in its sale to Celgene Corporation

Jacqueline has also provided ongoing corporate governance and securities law advice to many of the firm’s late stage and public company clients, including Alkermes, Altos Labs, Amarin Corporation, Citrix Systems, Juvenescence, Q32 Bio, Repligen, and Vigil Neuroscience.

Jacqueline is a member of the Massachusetts and Boston Bar Associations.

Jacqueline has been consistently selected for inclusion in The Legal 500 US for her work in M&A Middle Market ($500m-999m) since 2022. She was named an Acritas Star for 2019. The annual global report honors lawyers who exemplify professional excellence, innovation, and collaboration in the legal profession, and is based on over 6,500 interviews with clients around the world.

While attending law school, Jacqueline was the Note Editor of the Boston College Third World Law Journal for which she wrote “Eliminating Child Marriage in India: A Backdoor Approach to Alleviating Human Rights Violations” (Winter 2006).

Upon graduating from law school, Jacqueline was the recipient of the Richard G. Huber Award for her scholarship and leadership in extra and co-curricular activities.